Skye Bioscience, Inc. Amortization of Debt Discount (Premium)
Skye Bioscience, Inc. (SKYE) reported Amortization of Debt Discount (Premium) of $582.55 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-03-10
- Skye Bioscience, Inc. amortization of debt discount (premium) for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Skye Bioscience, Inc. amortization of debt discount (premium) for the quarter ending 2024-09-30 was $108.42K, a 8.87% increase year-over-year.
- Skye Bioscience, Inc. amortization of debt discount (premium) for the quarter ending 2024-06-30 was $243.33K.
- Skye Bioscience, Inc. amortization of debt discount (premium) for the quarter ending 2024-03-31 was $237.21K.
- Skye Bioscience, Inc. amortization of debt discount (premium) for fiscal 2024 was $582.55K, a 81.58% increase from fiscal 2023.
- Skye Bioscience, Inc. amortization of debt discount (premium) for fiscal 2023 was $320.83K, a 34.29% decline from fiscal 2022.
- Skye Bioscience, Inc. amortization of debt discount (premium) for fiscal 2022 was $488.24K, a 17.55% decline from fiscal 2021.
- Skye Bioscience, Inc. amortization of debt discount (premium) for fiscal 2021 was $592.15K, a 9.15% increase from fiscal 2020.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 3 month as first filed | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 6 month as first filed | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 9 month as first filed | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $108.42K derived: sum of 2 quarters · filed 2026-03-10 | $351.75K derived: sum of 3 quarters · filed 2026-03-10 | $582.55K 10-K · filed 2026-03-10 | ||||
| 2024-09-30 | $108.42K 10-Q · filed 2024-11-07 | $351.75K derived: sum of 2 quarters · filed 2024-11-07 | $582.55K 10-Q · filed 2024-11-07 | $810.19K derived: sum of 4 quarters · filed 2025-03-20 | ||||
| 2024-06-30 | $243.33K 10-Q · filed 2024-08-09 | $474.13K 10-Q · filed 2024-08-09 | $701.78K derived: sum of 3 quarters · filed 2025-03-20 | $801.36K derived: sum of 4 quarters · filed 2025-03-20 | ||||
| 2024-03-31 | $237.21K 10-Q · filed 2024-05-10 | $458.45K derived: sum of 2 quarters · filed 2025-03-20 | $558.03K derived: sum of 3 quarters · filed 2025-03-20 | $558.03K derived: sum of 4 quarters · filed 2025-03-20 | ||||
| 2023-12-31 | $221.24K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $320.83K derived: sum of 2 quarters · filed 2025-03-20 | $320.83K derived: sum of 3 quarters · filed 2025-03-20 | $320.83K 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $99.59K 10-Q · filed 2024-11-07 | $99.59K derived: sum of 2 quarters · filed 2024-11-07 | $99.59K 10-Q · filed 2024-11-07 | $108.69K derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | $9.11K derived: sum of 3 quarters · filed 2024-08-09 | $174.19K derived: sum of 4 quarters · filed 2024-08-09 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | $9.11K derived: sum of 2 quarters · filed 2024-05-10 | $174.19K derived: sum of 3 quarters · filed 2024-05-10 | $333.83K derived: sum of 4 quarters · filed 2024-05-10 | ||||
| 2022-12-31 | $9.11K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $174.19K derived: sum of 2 quarters · filed 2024-03-22 | $333.83K derived: sum of 3 quarters · filed 2024-03-22 | $488.24K 10-K · filed 2024-03-22 | ||||
| 2022-09-30 | $165.08K 10-Q · filed 2023-11-14 | $324.73K derived: sum of 2 quarters · filed 2023-11-14 | $479.13K 10-Q · filed 2023-11-14 | $633.45K derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $159.65K 10-Q · filed 2023-08-07 | $314.05K 10-Q · filed 2023-08-07 | $468.37K derived: sum of 3 quarters · filed 2023-08-07 | $619.22K derived: sum of 4 quarters · filed 2023-08-07 | ||||
| 2022-03-31 | $154.41K 10-Q · filed 2023-05-12 | $308.73K derived: sum of 2 quarters · filed 2023-05-12 | $459.58K derived: sum of 3 quarters · filed 2023-05-12 | $605.46K derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | $154.32K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $305.17K derived: sum of 2 quarters · filed 2023-03-31 | $451.06K derived: sum of 3 quarters · filed 2023-03-31 | $592.15K 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $150.85K 10-Q · filed 2022-11-14 | $296.74K derived: sum of 2 quarters · filed 2022-11-14 | $437.83K 10-Q · filed 2022-11-14 | $578.85K derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $145.88K 10-Q · filed 2022-08-15 | $286.98K 10-Q · filed 2022-08-15 | $428.00K derived: sum of 3 quarters · filed 2022-08-15 | $565.85K derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $141.10K 10-Q · filed 2022-05-06 | $282.11K derived: sum of 2 quarters · filed 2022-05-06 | $419.96K derived: sum of 3 quarters · filed 2022-05-06 | $553.27K derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | $141.02K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $278.87K derived: sum of 2 quarters · filed 2022-03-28 | $412.18K derived: sum of 3 quarters · filed 2022-03-28 | $542.52K 10-K · filed 2022-03-28 | $544.03K 10-K · filed 2021-03-02 | |||
| 2020-09-30 | $137.85K 10-Q · filed 2021-11-10 | $271.16K derived: sum of 2 quarters · filed 2021-11-10 | $401.51K 10-Q · filed 2021-11-10 | $402.62K 10-Q · filed 2020-11-06 | $591.84K derived: sum of 4 quarters · filed 2021-11-10 | |||
| 2020-06-30 | $133.31K 10-Q · filed 2021-08-06 | $263.66K 10-Q · filed 2021-08-06 | $264.39K 10-Q · filed 2020-08-13 | $453.99K derived: sum of 3 quarters · filed 2021-08-06 | $648.20K derived: sum of 4 quarters · filed 2021-08-06 | |||
| 2020-03-31 | $130.35K 10-Q · filed 2021-05-07 | $130.71K 10-Q · filed 2020-05-08 | $320.68K derived: sum of 2 quarters · filed 2021-05-07 | $514.89K derived: sum of 3 quarters · filed 2021-05-07 | $702.69K derived: sum of 4 quarters · filed 2021-05-07 | |||
| 2019-12-31 | $190.33K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $384.54K derived: sum of 2 quarters · filed 2021-03-02 | $572.34K derived: sum of 3 quarters · filed 2021-03-02 | $629.29K 10-K · filed 2021-03-02 | ||||
| 2019-09-30 | $194.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $382.01K derived: sum of 2 quarters · filed 2020-11-06 | $438.96K 10-Q · filed 2020-11-06 | $462.89K derived: sum of 4 quarters · filed 2020-11-06 | ||||
| 2019-06-30 | $187.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $244.75K 10-Q · filed 2020-08-13 | $268.68K derived: sum of 3 quarters · filed 2020-08-13 | $268.68K derived: sum of 4 quarters · filed 2020-08-13 | ||||
| 2019-03-31 | $56.95K 10-Q · filed 2020-05-08 | $80.88K derived: sum of 2 quarters · filed 2020-05-08 | $80.88K derived: sum of 3 quarters · filed 2020-05-08 | $80.88K derived: sum of 4 quarters · filed 2020-05-08 | ||||
| 2018-12-31 | $23.93K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $23.93K derived: sum of 2 quarters · filed 2020-03-23 | $23.93K derived: sum of 3 quarters · filed 2020-03-23 | $58.54K 10-K · filed 2020-03-23 | ||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | $34.61K 10-Q · filed 2019-11-14 | |||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $34.61K 10-Q · filed 2019-08-09 | ||||||
| 2018-03-31 | $34.61K 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |